Profound Medical (PROF) Receives Upgrade to Buy: Implications for the Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 19 2025
0mins
Should l Buy PROF?
Source: NASDAQ.COM
Zacks Rank Upgrade: Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices.
Earnings Estimates Impact: The Zacks rating system emphasizes the importance of changing earnings estimates, which are correlated with near-term stock price movements, making it a valuable tool for investors.
Market Positioning: The upgrade places Profound Medical in the top 20% of Zacks-covered stocks, indicating a strong potential for price appreciation based on improved earnings outlook.
Future Growth Potential: The article highlights the growing demand for data and the opportunities for semiconductor companies, suggesting that Profound Medical is well-positioned for future growth in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PROF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PROF
Wall Street analysts forecast PROF stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.410
Low
11.00
Averages
11.67
High
12.00
Current: 5.410
Low
11.00
Averages
11.67
High
12.00
About PROF
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Profound Medical Corp. Reports Q4 2025 Earnings Insights
- CAPTAIN Trial Progress: Profound Medical has completed recruitment for the CAPTAIN trial, the first multicenter randomized controlled trial comparing a new technology to robotic radical prostatectomy, establishing foundational clinical evidence that is expected to drive a new treatment paradigm for prostate disease management.
- Financial Performance Review: The company reported Q4 2025 revenue of $6 million, a 43% increase from $4.2 million in Q4 2024, with $2.3 million from recurring revenue and $3.7 million from one-time capital equipment sales, although gross margin declined from 71% to 67%.
- Future Outlook: Management reiterated expectations for high double-digit to low triple-digit revenue growth in 2026, aiming to increase the number of TULSA-PRO sites to approximately 120 by year-end, reflecting confidence in market expansion.
- Market Challenges and Opportunities: Despite facing gross margin pressures and operational scaling risks, management remains optimistic about future profitable growth, emphasizing the importance of increasing high-margin recurring revenue and advancing clinical milestones for sustainable growth.
See More
Profound Medical Q4 Earnings Beat Expectations
- Earnings Beat: Profound Medical reported a Q4 GAAP EPS of $0.27, exceeding expectations by $0.55, indicating improved profitability that may boost investor confidence.
- Significant Revenue Growth: The company achieved $6 million in revenue for Q4, reflecting a 42.9% year-over-year increase, although it fell short of expectations by $1.72 million, highlighting market demand volatility that could impact future financial forecasts.
- Financing Announcement: Profound Medical announced a financing plan of up to $40 million aimed at supporting future R&D and market expansion, which could provide essential funding for driving long-term growth.
- Quant Rating Update: Seeking Alpha's Quant Rating on Profound Medical indicates market interest in its future performance, prompting investors to closely monitor the company's strategic execution and market response.
See More
Profound Medical Receives 2025/2026 Mount Logan Award for Innovation
- Award Recognition: Profound Medical has been awarded the 2025/2026 Mount Logan Award, acknowledging its groundbreaking achievements in image-guided therapy and artificial intelligence, highlighting its international influence and innovation capabilities.
- Patient Treatment Milestone: The company has successfully treated its 4,000th TULSA Procedure patient, marking significant progress in treating prostate cancer and benign prostatic hyperplasia, further solidifying its market position.
- Strategic Partnerships and Market Expansion: Profound has secured new U.S. reimbursement codes and established partnerships to expand patient access globally, aiming to drive future growth potential for the company.
- Technological Innovation and Clinical Impact: The TULSA-PRO system utilizes real-time MRI and robotically controlled ultrasound technology to provide non-invasive treatment, significantly reducing patient recovery time and side effects, showcasing its broad application prospects in prostate disease treatment.
See More
Mount Sinai Performs First AI-Powered Prostate Treatment, Enhancing Patient Quality of Life
- Successful First Treatment: Mount Sinai Hospital has successfully performed its first TULSA-PRO® prostate cancer treatment, establishing its leadership in robotic surgical care, with the patient discharged the same day, demonstrating the efficiency and safety of the procedure.
- Technological Innovation: The TULSA Procedure™ employs robotically controlled ultrasound to precisely heat prostate tissue to 55-57°C, ensuring no bleeding or hospital stay while maximizing protection of patient nerves and physiological functions, thereby reducing postoperative side effects.
- Clinical Application Prospects: This technology is applicable not only for prostate cancer patients but also effectively treats benign prostatic hyperplasia (BPH), providing patients with more optimal treatment options and paving the way for future research and guideline development.
- Market Potential: Profound Medical's TULSA-PRO® system is CE marked and FDA 510(k) cleared, expected to become a mainstream treatment option for prostate diseases, addressing the growing market demand.
See More
Profound Medical Completes $6.45 Million Private Placement to Expand Operations
- Successful Financing: Profound Medical has completed a private placement to Canadian investors, issuing 921,428 common shares at $7 each, raising approximately $6.45 million, which enhances the company's financial strength for future growth.
- Clear Use of Proceeds: The funds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, indicating the company's commitment to market and technological innovation.
- Compliance Assurance: The securities issued are not registered under U.S. securities laws and are subject to a four-month hold period, ensuring the company operates within a compliant framework to mitigate legal risks.
- Broad Technological Prospects: Profound's TULSA-PRO system and Sonalleve platform show significant potential in the non-invasive treatment sector, with ongoing technological innovation and market expansion expected to enhance the company's competitiveness in the medical device industry.
See More
Profound Medical Corp. Raises $6.45 Million in Expanded Private Placement
- Increased Financing Size: Profound Medical Corp. has expanded its private placement to raise $6.45 million by issuing 921,428 common shares at $7 each, reflecting strong interest from long-term investors.
- Clear Use of Proceeds: The net proceeds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, aimed at enhancing the company's market competitiveness and innovation capabilities.
- Compliance Considerations: The securities offered will not be sold to U.S. purchasers, ensuring compliance with U.S. securities laws and reducing legal risks associated with the offering.
- Optimistic Market Outlook: Profound Medical focuses on developing incision-free treatment technologies, particularly the TULSA-PRO system, which is expected to drive growth in its market share within the prostate disease treatment sector.
See More
Profound Medical Corp. Reports Q4 2025 Earnings Insights
- CAPTAIN Trial Progress: Profound Medical has completed recruitment for the CAPTAIN trial, the first multicenter randomized controlled trial comparing a new technology to robotic radical prostatectomy, establishing foundational clinical evidence that is expected to drive a new treatment paradigm for prostate disease management.
- Financial Performance Review: The company reported Q4 2025 revenue of $6 million, a 43% increase from $4.2 million in Q4 2024, with $2.3 million from recurring revenue and $3.7 million from one-time capital equipment sales, although gross margin declined from 71% to 67%.
- Future Outlook: Management reiterated expectations for high double-digit to low triple-digit revenue growth in 2026, aiming to increase the number of TULSA-PRO sites to approximately 120 by year-end, reflecting confidence in market expansion.
- Market Challenges and Opportunities: Despite facing gross margin pressures and operational scaling risks, management remains optimistic about future profitable growth, emphasizing the importance of increasing high-margin recurring revenue and advancing clinical milestones for sustainable growth.
See More
Profound Medical Q4 Earnings Beat Expectations
- Earnings Beat: Profound Medical reported a Q4 GAAP EPS of $0.27, exceeding expectations by $0.55, indicating improved profitability that may boost investor confidence.
- Significant Revenue Growth: The company achieved $6 million in revenue for Q4, reflecting a 42.9% year-over-year increase, although it fell short of expectations by $1.72 million, highlighting market demand volatility that could impact future financial forecasts.
- Financing Announcement: Profound Medical announced a financing plan of up to $40 million aimed at supporting future R&D and market expansion, which could provide essential funding for driving long-term growth.
- Quant Rating Update: Seeking Alpha's Quant Rating on Profound Medical indicates market interest in its future performance, prompting investors to closely monitor the company's strategic execution and market response.
See More
Profound Medical Receives 2025/2026 Mount Logan Award for Innovation
- Award Recognition: Profound Medical has been awarded the 2025/2026 Mount Logan Award, acknowledging its groundbreaking achievements in image-guided therapy and artificial intelligence, highlighting its international influence and innovation capabilities.
- Patient Treatment Milestone: The company has successfully treated its 4,000th TULSA Procedure patient, marking significant progress in treating prostate cancer and benign prostatic hyperplasia, further solidifying its market position.
- Strategic Partnerships and Market Expansion: Profound has secured new U.S. reimbursement codes and established partnerships to expand patient access globally, aiming to drive future growth potential for the company.
- Technological Innovation and Clinical Impact: The TULSA-PRO system utilizes real-time MRI and robotically controlled ultrasound technology to provide non-invasive treatment, significantly reducing patient recovery time and side effects, showcasing its broad application prospects in prostate disease treatment.
See More
Mount Sinai Performs First AI-Powered Prostate Treatment, Enhancing Patient Quality of Life
- Successful First Treatment: Mount Sinai Hospital has successfully performed its first TULSA-PRO® prostate cancer treatment, establishing its leadership in robotic surgical care, with the patient discharged the same day, demonstrating the efficiency and safety of the procedure.
- Technological Innovation: The TULSA Procedure™ employs robotically controlled ultrasound to precisely heat prostate tissue to 55-57°C, ensuring no bleeding or hospital stay while maximizing protection of patient nerves and physiological functions, thereby reducing postoperative side effects.
- Clinical Application Prospects: This technology is applicable not only for prostate cancer patients but also effectively treats benign prostatic hyperplasia (BPH), providing patients with more optimal treatment options and paving the way for future research and guideline development.
- Market Potential: Profound Medical's TULSA-PRO® system is CE marked and FDA 510(k) cleared, expected to become a mainstream treatment option for prostate diseases, addressing the growing market demand.
See More
Profound Medical Completes $6.45 Million Private Placement to Expand Operations
- Successful Financing: Profound Medical has completed a private placement to Canadian investors, issuing 921,428 common shares at $7 each, raising approximately $6.45 million, which enhances the company's financial strength for future growth.
- Clear Use of Proceeds: The funds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, indicating the company's commitment to market and technological innovation.
- Compliance Assurance: The securities issued are not registered under U.S. securities laws and are subject to a four-month hold period, ensuring the company operates within a compliant framework to mitigate legal risks.
- Broad Technological Prospects: Profound's TULSA-PRO system and Sonalleve platform show significant potential in the non-invasive treatment sector, with ongoing technological innovation and market expansion expected to enhance the company's competitiveness in the medical device industry.
See More
Profound Medical Corp. Raises $6.45 Million in Expanded Private Placement
- Increased Financing Size: Profound Medical Corp. has expanded its private placement to raise $6.45 million by issuing 921,428 common shares at $7 each, reflecting strong interest from long-term investors.
- Clear Use of Proceeds: The net proceeds will be allocated for sales and marketing expansion, research and development, strategic transactions, and general corporate purposes, aimed at enhancing the company's market competitiveness and innovation capabilities.
- Compliance Considerations: The securities offered will not be sold to U.S. purchasers, ensuring compliance with U.S. securities laws and reducing legal risks associated with the offering.
- Optimistic Market Outlook: Profound Medical focuses on developing incision-free treatment technologies, particularly the TULSA-PRO system, which is expected to drive growth in its market share within the prostate disease treatment sector.
See More
